ScreenerHero

TCRT Alaunos Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · alaunos.com
0.8381USD+12.89%Mkt Cap: 2.45M $P/E: —

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.45M USD
Enterprise Value1.76M USD
Revenue (TTM)3.00K USD
Gross Profit-1.64M USD
Net Income (TTM)-4.18M USD
Revenue/Share0.0010 USD
Last Price0.8381 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.24
PEG0.58
EV/EBITDA-0.44
EV/Revenue587.41
P/S724.37
P/B2.83
EPS (TTM)-1.76
EPS (Forward)-0.60
52W Range
0.71903% of range4.590
52W High4.590 USD
52W Low0.7190 USD
Profitability
Gross Margin0.00%
Oper. Margin-135233.33%
EBITDA Margin0.00%
Profit Margin-83520.00%
ROE-193.96%
ROA-140.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.87M USD
CapEx (TTM)98.00K USD
FCF Margin-52354.17%
FCF Yield-64.02%
Net Debt-124.00K USD
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity—
Current Ratio0.77
Quick Ratio0.14
Book Value/Sh0.26 USD
Cash/Share0.05 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 18, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.93M
Float1.98M
Insiders13.28%
Institutions4.23%
Short Interest
Short Ratio0.5d
Short % Float0.26%
Short % Out.0.24%
Shares Short6.08K
Short (prev mo.)12.51K
Technical
SMA 501.571 (-46.7%)
SMA 2002.438 (-65.6%)
Beta-0.87
S&P 52W Chg16.45%
Avg Vol (30d)1.14M
Avg Vol (10d)114.09K
Technical Indicators
RSI (14)23.9
MACD-0.2502
MACD Signal-0.2305
MACD Hist.-0.0197
BB Upper1.768 USD
BB Middle1.171 USD
BB Lower0.5748 USD
BB Width101.84%
ATR (14)0.1154 USD
Vol Ratio (20d)0.18x